Subject
Obstetrics and Gynecology,Oncology
Reference17 articles.
1. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma;O'Malley;Gynecol. Oncol.,2022
2. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer;Swisher;Gyn. Oncol.,2021
3. SOLO1 investigators. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a brca mutation: the SOLO1/GOG 3004 trial;DiSilvestro;J. Clin. Oncol.,2022
4. Final overall survival results from the Phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer;Ray-Coquard,2022
5. Overall Survival Results From ARIEL4: A Phase 3 Study Assessing Rucaparib vs Chemotherapy in Patients With Advanced, Relapsed Ovarian Carcinoma and a Deleterious BRCA1/2 Mutation;Oza,2022
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献